Orforglipron is the first small molecule to act as an oral GLP-1 agonist"
Third, the heterogeneity in cognitive endpoints across clinical investigations hinders direct comparisons between studies
So, instead of stopping its use because of side effects, consider managing these side effects
California Department of Health Care Services spokesperson Tessa Outhyse said in an email that the official advice to try those other approaches now is not meant to dismiss any past efforts, but to encourage Medi-Cal members to take a renewed, proactive, and medically supported approach with their healthcare provider that may appropriately include these additional options. But that may be unrealistic, said Kurt Hong, founding director of the Center for Clinical Nutrition at Keck School of Medicine of USC
2 Borlaug BA, Sharma K, Shah SJ, Ho JE